Bell Investment Advisors’s GSK GSK Stock Holding History

Bell Investment Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.9K	Sell	208 -121	-37%	-$6.4K	﹤0.01%	682
2026 Q1	$18.2K	Buy	329 +181	+122%	+$9.81K	﹤0.01%	467
2025 Q4	$7.26K	Sell	148 -35	-19%	-$1.63K	﹤0.01%	822
2025 Q3	$7.9K	Buy	183 +19	+12%	+$742	﹤0.01%	722
2025 Q2	$6.3K	Buy	164 +19	+13%	+$726	﹤0.01%	882
2025 Q1	$5.62K	Sell	145 -111	-43%	-$4.06K	﹤0.01%	863
2024 Q4	$8.66K	Buy	256 +161	+169%	+$5.8K	﹤0.01%	666
2024 Q3	$3.88K	Hold	95	–	–	﹤0.01%	1065
2024 Q2	$3.66K	Hold	95	–	–	﹤0.01%	1080
2024 Q1	$4.07K	Hold	95	–	–	﹤0.01%	1034
2023 Q4	$3.52K	Sell	95 -15	-14%	-$538	﹤0.01%	1071
2023 Q3	$3.99K	Buy	110 +60	+120%	+$2.13K	﹤0.01%	929
2023 Q2	$1.78K	Buy	50 +15	+43%	+$538	﹤0.01%	1357
2023 Q1	$1.25K	Hold	35	–	–	﹤0.01%	1473
2022 Q4	$1.23K	Sell	35 -7	-17%	-$233	﹤0.01%	1496
2022 Q3	$1K	Sell	42 -13	-24%	-$493	﹤0.01%	1425
2022 Q2	$3K	Buy	+55	New	+$3.04K	﹤0.01%	946
2021 Q4	$4K	Sell	64 -12	-16%	-$624	﹤0.01%	862
2021 Q3	$4K	Buy	+76	New	+$3.82K	﹤0.01%	796

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Bell Investment Advisors's GSK Position: Q2 2026 in Review

Bell Investment Advisors reduced its GSK (GSK) stake by 37% in Q2 2026, selling an estimated $6.4K and leaving 208 shares worth $10.9K. The position accounts for ﹤0.01% of the portfolio, ranked #682.

Bell Investment Advisors first reported a position in GSK in Q3 2021 and has held it in 19 quarters since. The position peaked at $18.2K in Q1 2026. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Bell Investment Advisors held 208 shares of GSK worth $10.9K as of Q2 2026.
Bell Investment Advisors sold 121 GSK shares in Q2 2026, an estimated $6.4K.
GSK made up ﹤0.01% of Bell Investment Advisors's portfolio in Q2 2026, its #682 holding.
Bell Investment Advisors first reported a position in GSK in Q3 2021 and has held it in 19 quarters since.
Bell Investment Advisors's GSK position peaked at $18.2K in Q1 2026.
1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Bell Investment Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.